BioCryst licenses European rights for navenibart in hereditary angioedema, securing $70M upfront plus milestones and royalties.

BioCryst Pharmaceuticals has granted an Irish affiliate of Neopharmed Gentili exclusive rights to commercialize navenibart, a treatment for hereditary angioedema (HAE), in Europe. BioCryst will receive $70 million upfront, up to $275 million in future regulatory and sales milestones, and royalties ranging from 18% to 30% on net sales. This deal builds on their previous collaboration for ORLADEYO and leverages Neopharmed Gentili's European commercial expertise. The Phase 3 program for navenibart is progressing on schedule for a U.S. regulatory filing by the end of 2027, strengthening BioCryst's financial position and focus on the U.S. market while expanding its European presence.